Navigation Links
Drug May Slow Early Prostate Cancer: Study
Date:1/24/2012

By Denise Mann
HealthDay Reporter

TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.

Prostate cancer can grow and spread slowly, which is why some men are urged to engage in so-called watchful waiting when the cancer is first diagnosed. Avodart (dutasteride) may help such men feel comfortable with surveillance as opposed to radical treatment, the researchers noted.

"The concept of active surveillance is gaining traction in most parts of the world," said study author Dr. Neil E. Fleshner, head of the division of urology at the Princess Margaret Hospital in Toronto. Still, some men are uncomfortable with doing nothing in the face of a cancer diagnosis, he said. "By using this drug, we can improve the proportion of men who remain committed to the surveillance."

The findings are published online Jan. 25 in The Lancet.

According to the U.S. National Cancer Institute, one out of every six men in the United States will develop prostate cancer in his lifetime. But because many of those cancers are low-grade, most will die of something else.

Avodart belongs to a class of drugs called 5-alpha reductase inhibitors. These drugs work by interfering with the effects of certain male hormones on the prostate. In the three-year study, prostate cancer progressed in 38 percent of 144 men with early prostate cancer who were treated with Avodart and 48 percent of the 145 men who received a placebo.

Men seem less anxious about the cancer diagnosis when they are doing something more proactive, Fleshner said. "The drug augments active surveillance and avoids most of the side effects associated with surgery and radiation," he said. Prostate removal surgery and/or radiation can lead to impotence and incontinence, he said.

The medication does have side effects, however, including reversible breast enlargement and tenderness and some sexual dysfunction.

"We know that we are over-treating prostate cancer," said Dr. Louis Potters, chairman of radiation medicine at North Shore University Hospital and Long Island Jewish Medical Center in Manhasset, N.Y.

"In the U.S., patients have a tendency to hear the word 'cancer,' and want to treat it right away," he said. "In these men with early prostate cancer, we can now say, 'Let's put you on this medication, and see what happens over the next couple of months.'"

However, some experts have concerns about 5-alpha reductase inhibitors. The U.S. Food and Drug Administration recently issued a warning that men who take these drugs to treat enlarged prostate glands may be at increased risk for high-grade prostate cancer.

Dr. Ryan Terlecki, an assistant professor of urology at Wake Forest Baptist Medical Center in Winston-Salem, N.C., said this may dampen enthusiasm for use of the drug to treat cancer.

"The overall role that these medications will play for urologists will decrease," Terlecki said. Doctors will likely begin looking toward noninvasive and/or non-medical treatments such as the use of thermal heat to cope with some of the symptoms of prostate conditions, he added.

More information

Learn more about prostate cancer at the American Cancer Society.

SOURCES: Neil E. Fleshner, M.D., head, division of urology, Princess Margaret Hospital, Toronto; Louis Potters, M.D., chairman, radiation medicine, North Shore University Hospital and LIJ Medical Center, Manhasset, N.Y.; Ryan Terlecki, M.D., assistant professor, urology, Wake Forest University, Winston-Salem, N.C.; Jan. 25, 2012, The Lancet, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rate of physician referrals nearly doubled
2. Small Stem Cell Study Claims Early Success in Treating Eye Disease
3. New test offers greater accuracy in early detection of colorectal cancer
4. JCI online early table of contents: Jan. 17, 2012
5. Is Continued Lip-Reading an Early Sign of Autism?
6. Tests Might Someday Help Spot Early Lung Cancer
7. Disruption of biological clocks causes neurodegeneration, early death
8. Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer
9. Hopkins researchers find Google Flu Trends a powerful early warning system for emergency departments
10. JCI online early table of contents: Jan. 9, 2012
11. Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug May Slow Early Prostate Cancer: Study
(Date:8/16/2017)... ... August 16, 2017 , ... ... their doors. They celebrate 30 years in business this year, and they’re marking ... inviting, tranquil space to serve their patients. , It stands to reason ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding from ... Health and Human Services. , This funding marks, the fourth time the HRSA ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA ... endoscope after every reprocessing cycle, both between patient procedures and before storage, is ... Drying is as important to the prevention of disease transmission and nosocomial infection ...
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... First ... United States, named Dr. Douglas J. Harrison, as the new Medical Director of its ... the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
(Date:8/7/2017)... FLINT, Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: ... for the quarter ended June 30, 2017.  All comparisons, unless ... Second Quarter 2017 ... compared to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology: